Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-501 (CNTF) for Retinitis Pigmentosa and Usher Syndrome
NCT01530659Phase 2Completed
- Sponsor
- Neurotech Pharmaceuticals, Inc.
- Start
- Jan 2012
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ciliary neurotrophic factor in retinitis pigmentosa (RP), Usher syndrome type 2 (USH2), Usher syndrome type 3, sponsored by Neurotech Pharmaceuticals, Inc.. Started Jan 2012; status: completed.
02
Drugs
ciliary neurotrophic factor
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2 (USH2)Usher syndrome type 3
Beyond the preview
Go deeper on NCT01530659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01530659.